{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:12Z","timestamp":1760733612691,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["1520190"],"award-info":[{"award-number":["1520190"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea (NRF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT & Future Planning","doi-asserted-by":"publisher","award":["2017R1A2B2005772","2016R1C1B2014671"],"award-info":[{"award-number":["2017R1A2B2005772","2016R1C1B2014671"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-2016M3A9E8941664"],"award-info":[{"award-number":["NRF-2016M3A9E8941664"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ejca.2018.11.029","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T19:11:29Z","timestamp":1553022689000},"page":"20-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-6155","authenticated-orcid":false,"given":"Chan","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minkyu","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung Mo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Song","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beodeul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Cheol","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-4531","authenticated-orcid":false,"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ejca.2018.11.029_bib1","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1200\/JCO.2006.05.9758","article-title":"Disparities in gastric cancer chemotherapy between the East and West","volume":"24","author":"Ohtsu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.029_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10120-013-0297-z","article-title":"Optimal chemotherapy for advanced gastric cancer: is there a global consensus?","volume":"17","author":"Lordick","year":"2014","journal-title":"Gastric Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2018.11.029_bib3","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.3748\/wjg.v20.i14.3905","article-title":"Treatment options in patients with metastatic gastric cancer: current status and future perspectives","volume":"20","author":"Bilici","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.029_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.029_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2014","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2018.11.029_bib6","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2018.11.029_bib7","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","article-title":"Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"19","author":"Al-Batran","year":"2008","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2018.11.029_bib8","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2017.35.15_suppl.4004","volume":"35","author":"Al-Batran","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.029_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdu496","article-title":"Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study","volume":"26","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2018.11.029_bib10","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1158\/1078-0432.CCR-05-2425","article-title":"Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer","volume":"12","author":"Yoshida","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.029_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00001813-200602000-00015","article-title":"Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil","volume":"17","author":"Park","year":"2006","journal-title":"Anti Cancer Drugs"},{"issue":"4","key":"10.1016\/j.ejca.2018.11.029_bib12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4143\/crt.2009.41.4.196","article-title":"Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials","volume":"41","author":"Chon","year":"2009","journal-title":"Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.029_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1179\/1973947814Y.0000000169","article-title":"Paclitaxel-based regimens as first-line treatment in advanced gastric cancer","volume":"27","author":"Guo","year":"2015","journal-title":"J Chemother"},{"issue":"5","key":"10.1016\/j.ejca.2018.11.029_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1586\/14737140.2015.1026807","article-title":"Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer","volume":"15","author":"Shi","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"69","key":"10.1016\/j.ejca.2018.11.029_bib15","doi-asserted-by":"crossref","first-page":"113494","DOI":"10.18632\/oncotarget.23054","article-title":"PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2018.11.029_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2307\/2532552","article-title":"Selection designs for pilot studies based on survival","author":"Liu","year":"1993","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.029_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01243894-200601000-00003","article-title":"Pick the winner designs in phase II cancer clinical trials","volume":"1","author":"Mandrekar","year":"2006","journal-title":"J Thoracic Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.029_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.ejca.2018.11.029_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.11.029_bib20","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/annonc\/mdv316","article-title":"Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and\/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)","volume":"26","author":"Ryu","year":"2015","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2018.11.029_bib21","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1158\/1078-0432.CCR-04-0469","article-title":"Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies","volume":"10","author":"Chu","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ejca.2018.11.029_bib22","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1016\/j.ejca.2013.07.003","article-title":"Combination of cisplatin\/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin\/5-fluorouracil in the First-Line Advanced Gastric Cancer Study","volume":"49","author":"Ajani","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.029_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.bjc.6604861","article-title":"Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer","volume":"100","author":"Han","year":"2009","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.029_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2407-8-148","article-title":"Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker","volume":"8","author":"Keam","year":"2008","journal-title":"BMC Canc"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.029_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00432-013-1563-5","article-title":"Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)","volume":"140","author":"Koizumi","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2018.11.029_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cas.12647","article-title":"Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose","volume":"106","author":"Kenmotsu","year":"2015","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.ejca.2018.11.029_bib27","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.3892\/ol.2016.4337","article-title":"Lauren classification and individualized chemotherapy in gastric cancer","volume":"11","author":"Ma","year":"2016","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.ejca.2018.11.029_bib28","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.21873\/anticanres.11138","article-title":"Signet ring cells and efficacy of first-line chemotherapy in advanced gastric or oesogastric junction adenocarcinoma","volume":"36","author":"Lemoine","year":"2016","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2018.11.029_bib29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/SLA.0000000000001793","article-title":"Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia","volume":"265","author":"Chon","year":"2017","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.029_bib30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1477-7819-12-280","article-title":"Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute","volume":"12","author":"Sun","year":"2014","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejca.2018.11.029_bib31","first-page":"1","article-title":"The clinical implications of FDG-PET\/CT differ according to histology in advanced gastric cancer","author":"Chon","year":"2018","journal-title":"Gastric Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2018.11.029_bib32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","article-title":"Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study","volume":"10","author":"Boku","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.029_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s101200200015","article-title":"Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer","volume":"5","author":"Yamaguchi","year":"2002","journal-title":"Gastric Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2018.11.029_bib34","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.ejca.2013.05.022","article-title":"Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer","volume":"49","author":"Kawakami","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2018.11.029_bib35","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.11.029_bib36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrclinonc.2016.15","article-title":"Clinical impact of tumour biology in the management of gastroesophageal cancer","volume":"13","author":"Lordick","year":"2016","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:24Z","timestamp":1760732604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":36,"alternative-id":["S0959804918315363"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}